The CRISTALLO trial showed that venetoclax plus obinutuzumab achieved high minimal residual disease negativity as a frontline ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

A COVID-19 diagnosis is no longer as frightening as it used to be, thanks to developments in treatment choices. However, a ...

During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after ...

A new international study has found that a simple tablet treatment could improve survival rates for people with chronic ...

Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

An international study of over 800 chronic lymphocytic leukemia (CLL) patients found that an all-tablet therapy of ...

The study enrolled 523 patients with untreated CLL, randomly assigning them to receive either MRD-driven ibrutinib-venetoclax therapy or standard FCR. After a median follow-up of 43.7 months ...

The Rai and Binet staging systems are globally used to predict CLL disease progression and guide treatment decisions. The Rai staging system classifies CLL progression into 3 risk categories: low risk ...

Ibrutinib normalizes RBC aggregation in CLL, potentially reducing thrombotic risks by mitigating blood flow complications. Obinutuzumab/venetoclax combination does ...

Fungal and opportunistic infections are rare in patients with untreated CLL. 2 Autoimmune hemolytic anemia is mediated by autoantibodies directed against red blood cells, causing their premature ...